# NuVision Biotherapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvision-biotherapies

- Industry: Biotechnology
- Headquarters: Nottingham, UK
- Website: www.nu-vision.co.uk
- Total disclosed funding: $0.6M
- Latest round: Seed (Jul 14, 2015)
- Investors on record: 1

## About

NuVision Biotherapies Limited develops innovative ocular therapies, focusing on advanced products for eye care professionals to enhance healing and treatment options for ocular surface diseases. Founded in 2015 by founder Andrew Hopkinson in Nottingham, UK, NuVision Biotherapies Limited specializes in ocular therapies. In January 2026, NuVision Biotherapies Limited raised GBP 4.8 million in venture funding led by Mercia Asset Management, with participation from University of Nottingham and Pioneer Group. NuVision Biotherapies specializes in innovative ocular therapies, primarily focusing on two key product offerings: Omnigen and OmniLenz. Omnigen is a wound dressing and grafting material derived from amniotic membrane, designed to provide a natural barrier that supports healing for ocular surface diseases and injuries. The product retains the membrane's essential barrier functions through a proprietary processing method, ensuring that it can be conveniently stored and accessed in a range of clinical settings. OmniLenz, on the other hand, presents a bespoke contact lens solution aimed at delivering rapid care without the need for surgical intervention. These products are primarily targeted towards eye care specialists and clinicians, serving a diverse clientele that includes hospitals, outpatient clinics, and private practices across Europe and North America. By addressing the urgent need for effective and accessible ocular care, NuVision Biotherapies is positioning itself to cater to the growing demand for advanced treatments in the ophthalmology sector. NuVision Biotherapies generates revenue through direct sales of its flagship products, Omnigen and OmniLenz, to healthcare providers within the ophthalmology market. The company operates on a business-to-business (B2B) model, where transactions occur primarily between NuVision and its clients, including hospitals and eye care clinics. These transactions typically involve bulk orders of products tailored to the specific needs of the eye care professionals, allowing for a streamlined supply chain. While specific pricing details for these offerings are not disclosed, it is understood that the sales structure may involve negotiated contracts that take into account the volume and frequency of orders. Through these established relationships, NuVision Biotherapies aims to sustain recurring revenue from its innovative therapies, thereby supporting its ongoing mission to enhance ocular health outcomes globally. In February 2026, NuVision Biotherapies Limited raised GBP 4.8 million in venture funding led by returning investor Mercia Asset Management, with participation from another returning investor University of Nottingham. New investor Pioneer Group and other unspecified investors also participated in the round. The company plans the January 2026 funding to expand operations and its development efforts.

## Funding rounds

- Seed, Jul 14, 2015, $0.6M — Mercia Asset Management

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Seed